Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Agency for Care Effectiveness (ACE)	Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023	Ontario Health	Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Valoctocogene roxaparvovec (severe haemophilia A)]
2023	Agency for Care Effectiveness (ACE)	The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023	Agency for Care Effectiveness (ACE)	Paige Prostate Detect to assist the diagnosis of prostate cancer
2023	Health Information and Quality Authority (HIQA)	Ultra-hypofractionated adjuvant radiotherapy for breast cancer: evidence synthesis to support a generic justification decision
2023	Agency for Care Effectiveness (ACE)	HeartFlow FFRCT for the diagnosis of coronary artery disease
2023	Health Information and Quality Authority (HIQA)	An overview of national approaches to stockpiling of medical countermeasures for public health emergencies
2023	Agency for Care Effectiveness (ACE)	Rapid to aid the diagnosis of patients suspected of stroke
2023	Health Technology Wales (HTW)	Multi-grip myoelectric upper-limb prosthetics
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of spinal muscular atrophy (SMA) to the National Newborn Bloodspot Screening Programme
2023	Agency for Care Effectiveness (ACE)	AcQMap for patients with cardiac arrhythmia
2023	NIHR Health Technology Assessment programme	Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study
2023	Agency for Care Effectiveness (ACE)	KardiaMobile for the detection of atrial fibrillation
2023	Health Information and Quality Authority (HIQA)	Repatriation of paediatric haematopoietic stem cell transplant services to Ireland: a Health Technology Assessment
2023	NIHR Health Technology Assessment programme	Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies
2023	Health Information and Quality Authority (HIQA)	A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage invasive breast cancer
2023	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
2023	Norwegian Institute of Public Health (NIPH)	Transcutaneous non-invasive vagus nerve stimulation (gammaCore) for the treatment of cluster headache: A single technology assessment
2023	NIHR Health Services and Delivery Research programme	Factors which facilitate or impede patient engagement with pulmonary and cardiac rehabilitation: a rapid evaluation mapping review
2023	Norwegian Institute of Public Health (NIPH)	Stockholm3 test to estimate the risk of prostate cancer: a single technology assessment
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The clinical effectiveness of denosumab (Prolia) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
2023	NIHR Health Services and Delivery Research programme	A multimethod study of NHS 111 online
2023	Norwegian Institute of Public Health (NIPH)	Oncotype DX breast cancer recurrence score test: a single technology assessment
2023	NIHR Health Services and Delivery Research programme	Thinking ahead about medical treatments in advanced illness: a qualitative study of barriers and enablers in end-of-life care planning with patients and families from ethnically diverse backgrounds
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Eladocagene exuparvovec (Aromatic-L-amino acid decarboxylase (AADC) deficiency, ≥ 18 months)]
2023	NIHR Health Services and Delivery Research programme	Towards achieving interorganisational collaboration between health-care providers: a realist evidence synthesis
2023	NIHR Health Services and Delivery Research programme	Early evaluation of the Children and Young People's Mental Health Trailblazer programme: a rapid mixed-methods study
2023	NIHR Health Services and Delivery Research programme	New and emerging technology for adult social care - the example of home sensors with artificial intelligence (AI) technology
2023	NIHR Health Services and Delivery Research programme	Youth violence intervention programme for vulnerable young people attending emergency departments in London: a rapid evaluation
2023	NIHR Health Services and Delivery Research programme	The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. Update 2023
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas. Update 2023
2023	Austrian Institute for Health Technology Assessment (AIHTA)	177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: Update 2023 - systematic review
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous aspiration thrombectomy for pulmonary embolism
2023	Agency for Care Effectiveness (ACE)	Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor
2023	Institute for Clinical and Economic Review (ICER)	Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023	Agency for Care Effectiveness (ACE)	Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Bleomycin electrosclerotherapy for vascular anomalies
2023	Institute for Clinical and Economic Review (ICER)	Lecanemab for early Alzheimer’s disease
2023	Agency for Care Effectiveness (ACE)	Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Electrical auricular vagus nerve stimulation for pain
2023	Institute for Clinical and Economic Review (ICER)	Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023	Agency for Care Effectiveness (ACE)	Echinocandins for treating invasive candidiasis
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Nurse-driven protocols for antibiotic initiation in febrile neutropenia
2023	Institute for Clinical and Economic Review (ICER)	Gene therapies for sickle cell disease
2023	Institute for Clinical and Economic Review (ICER)	Atidarsagene autotemcel for metachromatic leukodystrophy
2023	Malaysian Health Technology Assessment (MaHTAS)	Bio-electrical impedance analysis for the assessment of sarcopenia in elderly
2023	Malaysian Health Technology Assessment (MaHTAS)	Nasojejunal tube in upper gastrointestinal conditions
2023	Adelaide Health Technology Assessment (AHTA)	Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
2023	NIHR Health Technology Assessment programme	Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
2023	Malaysian Health Technology Assessment (MaHTAS)	Human skin allograft for burns
2023	Health Information and Quality Authority (HIQA)	Lutetium oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs): evidence synthesis to support a generic justification decision
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)
2023	Malaysian Health Technology Assessment (MaHTAS)	Negative pressure wound therapy
2023	Health Information and Quality Authority (HIQA)	A slot-scanning, biplanar, digital X-ray imaging system for the evaluation and monitoring of orthopaedic conditions: evidence synthesis to support a generic justification decision
2023	Health Information and Quality Authority (HIQA)	Analysis of public consultation surveys to inform the work of the Public Health Reform Expert Advisory Group [protocols and report]
2023	National Institute for Health and Care Excellence (NICE)	Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment. NICE HealthTech guidance 696
2023	Health Information and Quality Authority (HIQA)	Interventions to improve long COVID symptoms: a systematic review
2023	Health Information and Quality Authority (HIQA)	Methods for generic justification of new practices in ionising radiation
2023	Health Information and Quality Authority (HIQA)	Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023	Health Technology Wales (HTW)	Control contact lenses and spectacles for the treatment of myopia in children
2023	National Institute for Health and Care Excellence (NICE)	Digitally enabled therapies for adults with depression: early value assessment. NICE HealthTech guidance 675
2023	National Institute for Health and Care Excellence (NICE)	ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment. NICE HealthTech guidance 664
2023	Scottish Health Technologies Group (SHTG)	Priorities for the north imaging alliance
2023	National Institute for Health and Care Excellence (NICE)	Digital technologies for delivering multidisciplinary weight-management services: early value assessment. NICE HealthTech guidance 700
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	Scottish Health Technologies Group (SHTG)	Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023	National Institute for Health and Care Excellence (NICE)	Digitally enabled therapies for adults with anxiety disorders: early value assessment. NICE HealthTech guidance 676
2023	WorkSafeBC	Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023	Scottish Health Technologies Group (SHTG)	Technology-enabled theatre scheduling systems
2023	National Institute for Health and Care Excellence (NICE)	Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment. NICE HealthTech guidance 701
2023	WorkSafeBC	Causal association between carpal tunnel release surgery and trigger finger
2023	Scottish Health Technologies Group (SHTG)	Digital prevention programme for people at risk of type 2 diabetes
2023	National Institute for Health and Care Excellence (NICE)	Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023	National Institute for Health and Care Excellence (NICE)	Virtual ward platform technologies for acute respiratory infections: early value assessment. NICE HealthTech guidance 697
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Trends in utilisation of ultrasound by older Australians (2010-2019)
2023	WorkSafeBC	Platelet rich plasma in treating (recurrent) anterior shoulder dislocation
2023	National Institute for Health and Care Excellence (NICE)	Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023	National Institute for Health and Care Excellence (NICE)	Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment. NICE HealthTech guidance 695
2023	WorkSafeBC	Esketamine as treatment for depression and PTSD
2023	National Institute for Health and Care Excellence (NICE)	Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023	National Institute for Health and Care Excellence (NICE)	KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment. NICE HealthTech guidance 694
2023	WorkSafeBC	Botulinum toxin as treatment for neck strains
2023	National Institute for Health and Care Excellence (NICE)	Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023	National Institute for Health and Care Excellence (NICE)	Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment. NICE HealthTech guidance 660
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Sutimlimab (cold agglutinin disease)]
2023	WorkSafeBC	Migraines and the (Moderna) COVID-19 vaccine
2023	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023	National Institute for Health and Care Excellence (NICE)	Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment. NICE HealthTech guidance 665
2023	WorkSafeBC	Causal association between COVID-19 infection and irritable larynx syndrome
2023	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023	National Institute for Health and Care Excellence (NICE)	Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment. NICE HealthTech guidance 674
2023	WorkSafeBC	Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023	WorkSafeBC	Platelet rich plasma as treatment for medial epicondylitis
2023	National Institute for Health and Care Excellence (NICE)	Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023	National Institute for Health and Care Excellence (NICE)	CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment. NICE HealthTech guidance 663
2023	WorkSafeBC	Flotation therapy as treatment for concussions